TheraVet SA

ENXTPA:ALVET Stock Report

Market Cap: €302.0k

TheraVet Valuation

Is ALVET undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALVET when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALVET's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALVET's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALVET?

Key metric: As ALVET is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALVET. This is calculated by dividing ALVET's market cap by their current revenue.
What is ALVET's PS Ratio?
PS Ratio0.3x
Sales€918.32k
Market Cap€301.95k

Price to Sales Ratio vs Peers

How does ALVET's PS Ratio compare to its peers?

The above table shows the PS ratio for ALVET vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.1x
GV Genomic Vision Société Anonyme
0.4xn/a€692.9k
ALMDP Medesis Pharma
33.4xn/a€2.1m
ALINT IntegraGen
0.3xn/a€2.9m
ALVIO Valerio Therapeutics Société anonyme
6.3xn/a€11.9m
ALVET TheraVet
0.3xn/a€285.5k

Price-To-Sales vs Peers: ALVET is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (10.1x).

Price to Sales Ratio vs Industry

How does ALVET's PS Ratio compare vs other companies in the FR Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.7x31.8%
ALVET TheraVet
 0.3xn/aUS$296.81k
ALGEN genOway Société anonyme
1.2xn/aUS$35.22m
LYS Lysogene
0.4xn/aUS$5.42m
ALVET 0.3xIndustry Avg. 3.7xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.7x4.6%
ALVET TheraVet
 0.3xn/aUS$296.81k
No more companies

Price-To-Sales vs Industry: ALVET is good value based on its Price-To-Sales Ratio (0.3x) compared to the French Biotechs industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is ALVET's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALVET PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALVET's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sanofi

€116.8b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€93.17

7D

2.0%

1Y

7.9%

Eurofins Scientific

€8.9b

Provides various analytical testing and laboratory services worldwide.

ERF

€46.96

7D

3.3%

1Y

-12.0%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

7D

0%

1Y

-57.2%